An interventional study of Biomarker based IVD tests in Healthy, sponsored by Firalis SA. Recruiting at 1 site in France. Open to participants aged 18 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-24.
Sponsored by Firalis SA · Not applicable, Interventional, and Diagnostic
Stability studies on the peripheral biomarkers (lncRNAs, sncRNAs, mRNAs, proteins, lipids/metabolites) measured by Firalis IVD test candidates and effect of gender, age, nutrition on their expression level
Firalis SA and its affiliate Amoneta Diagnostics SAS are developing novel in-vitro diagnostic (IVD) tests for diverse diagnostic applications for major human diseases, including cardiovascular, and neurodegenerative disorders. These tests measure in blood and other peripheral body fluids; long non-coding RNAs (lncRNAs), small non-coding RNAs (sncRNAs), messenger RNAs (mRNAs), circulating proteins, lipids and metabolites. In addition, since 2020, Firalis is producing the salivary test EasyCOV for detection of Covid-19 positivity in both symptomatic and asymptomatic subjects. Firalis group is the sponsor of a pipeline of various clinical studies conducted in diverse National and European clinical sites of excellence, enrolling patients affected by the targeted diseases studied such as acute myocardial injury, Alzheimer disease for the proof of performance phase of the biomarkers and IVD test candidates. The present specific study aims to collect biological samples to complete the analytical validation of its diverse IVD tools namely the evaluation of the stability of the biomarkers and the effect of age, gender, nutrition and inter-period on the expression level of the studied biomarkers.
Exclusion Criteria:
Any subject who reports in the questionnaire of the screening period having one of the following diseases is excluded:
Healthy Volunteers will be recruited into the study
Diagnostic Test: Biomarker based IVD tests
Biomarker based IVD tests
lncRNA Biomarker expression before breakfast intake
lncRNA expression in count per million measured in blood plasma and whole blood paxgene samples
Time frame: T0- Baseline in the morning before breakfast at fasting conditions
lncRNA Biomarker expression after breakfast intake
lncRNA expression in count per million measured in blood plasma and whole blood paxgene samples
Time frame: T1- 1 hour after breakfast
sncRNA Biomarker expression before breakfast intake
sncRNA cycle threshold measured in blood plasma
Time frame: T0- Baseline in the morning before breakfast at fasting conditions
sncRNA Biomarker expression after breakfast intake
sncRNA cycle threshold measured in blood plasma
Time frame: T1- 1 hour after breakfast
mRNAs Biomarker expression before breakfast intake
mRNAs cycle threshold measured in blood plasma
Time frame: T0- Baseline in the morning before breakfast at fasting conditions
mRNAs Biomarker expression after breakfast intake
mRNAs cycle threshold measured in blood plasma
Time frame: T1- 1 hour after breakfast
Soluble proteins Biomarker expression before breakfast intake
Soluble proteins expression in ng/mL measured in blood plasma
Time frame: T0- Baseline in the morning before breakfast at fasting conditions
Soluble proteins Biomarker expression after breakfast intake
Soluble proteins expression in ng/mL measured in blood plasma
Time frame: T1- 1 hour after breakfast
Plan to share: No
No publications or documents are linked to this record.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Firalis SA